Kiadis Pharma announced today that its lead product ATIR™ has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for...
read more (NL version)
Biopharmaceutical company Kiadis Pharma announces today the clinical development collaboration for its lead product ATIR™ with Dr. Stephan Mielke and...
read more (NL version)